LIBTAYO can help your
immune system fight
advanced CSCC

What is LIBTAYO?

LIBTAYO is a medicine approved by the Food and Drug Administration (FDA) to treat cutaneous squamous cell carcinoma (CSCC) that has spread or cannot be cured by surgery or radiation.

What is immunotherapy?

Immunotherapy can help the body’s immune system fight cancer. LIBTAYO is a type of immunotherapy treatment called a programmed death receptor-1 (PD-1) inhibitor. LIBTAYO is not chemotherapy or radiation therapy.

Is LIBTAYO right for me?

LIBTAYO may be right for people with advanced CSCC that:

has spread (metastasized)


cannot be
cured by surgery or radiation

In 2 ongoing clinical trials:

  • 47.2% of patients (51 of 108) saw an improvement in their condition with LIBTAYO (objective response rate)
  • 61% of patients (31 of 51) who responded to LIBTAYO had responses that lasted 6 months or longer
  • Responses lasted between 1 month and 15.2+ months (still ongoing at time of last follow-up)
Ask your healthcare provider whether LIBTAYO is a treatment option you should consider.

Meaningful Story.
Meaningful Hope.

Actual patient. Individual results may vary.

Meet Chris

Chris shares her story about living with metastatic CSCC. Listen as she takes you through her journey, from initially being misdiagnosed to the chaIlenges she faces managing life with metastatic CSCC, and her treatment experience with LIBTAYO.

Please see full Prescribing Information, including Medication Guide.